

Serial No. 10/020,450
Docket No. 0109-UTL
Reply to Office action of July 8, 2003

I. AMENDMENTS

Please enter the following amendments without prejudice or disclaimer. This listing of claims will replace all prior versions, and listings, of claims in the application.

In the Claims:

Please cancel claims 3, 5, 7, 8, 24-32, 39-41, and 48-50 without prejudice. Applicants reserve the right to prosecute these claims in a continuation or divisional application.

1. (Previously presented) A method for treating and/or ameliorating a symptom of neuronal damage associated with a cerebral ischemic condition in a mammalian subject, comprising administering to the subject an effective amount of a non-alpha tocopherol enriched tocopherol composition, and by said administering, reducing neuronal damage related to said cerebral ischemic condition.
2. (Original) The method of claim 1 wherein the non-alpha tocopherol enriched tocopherol composition is a gamma-tocopherol enriched tocopherol composition.
3. (Canceled)
4. (Original) The method of claim 1 wherein the non-alpha tocopherol enriched tocopherol composition is a beta-tocopherol enriched tocopherol composition.
5. (Canceled)
6. (Original) The method of claim 1 wherein the non-alpha tocopherol enriched tocopherol composition is a delta-tocopherol enriched tocopherol composition.
7. (Canceled)
8. (Canceled)
9. (Original) The method of claim 1 wherein the cerebral ischemic condition is secondary to an occlusion of the cerebral vasculature.

Serial No. 10/020,450
Docket No. 0109-UTL
Reply to Office action of July 8, 2003

7 10. (Previously presented) The method of claim 9 wherein the occlusion is due to a thromboembolus.

7 11. (Original) The method of claim 1 wherein the cerebral ischemia is due to a spasm of the coronary vasculature.

8 12. (Original) The method of claim 1 wherein the cerebral ischemic condition is secondary to a cessation of cardiac function.

9 13. (Original) The method of claim 1 wherein the cerebral ischemic condition is secondary to a cardiopulmonary bypass procedure.

10 14. (Original) The method of claim 1 wherein the cerebral ischemic condition is secondary to a hemorrhagic event in the cerebral vasculature.

11 15. (Original) The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 60% gamma-tocopherol.

12 16. (Original) The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 65% gamma-tocopherol.

13 17. (Original) The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 70% gamma-tocopherol.

14 18. (Original) The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 75% gamma-tocopherol.

15 19. (Original) The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 80% gamma-tocopherol.

16 20. (Original) The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 85% gamma-tocopherol.

17 21. (Original) The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 90% gamma-tocopherol.

18 22. (Original) The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 95% gamma-tocopherol.

Serial No. 10/020,450
Docket No. 0109-UTL
Reply to Office action of July 8, 2003

19 ~~23.~~ (Original) The method of claim 2 wherein said gamma-tocopherol enriched tocopherol composition comprises at least 98% gamma-tocopherol.

24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Canceled)

26 ~~33.~~ (Original) The method of claim ~~4~~ wherein said beta-tocopherol enriched tocopherol composition comprises at least 50% beta-tocopherol.

27 ~~34.~~ (Original) The method of claim ~~4~~ wherein said beta-tocopherol enriched tocopherol composition comprises at least 65% beta-tocopherol.

28 ~~35.~~ (Original) The method of claim ~~4~~ wherein said beta-tocopherol enriched tocopherol composition comprises at least 75% beta-tocopherol.

29 ~~36.~~ (Original) The method of claim ~~4~~ wherein said beta-tocopherol enriched tocopherol composition comprises at least 90% beta-tocopherol.

27 ~~37.~~ (Original) The method of claim ~~4~~ wherein said beta-tocopherol enriched tocopherol composition comprises at least 95% beta-tocopherol.

25 ~~38.~~ (Original) The method of claim ~~4~~ wherein said beta-tocopherol enriched tocopherol composition comprises at least 98% beta-tocopherol.

39. (Canceled)

40. (Canceled)

41. (Canceled)

Serial No. 10/020,450
Docket No. 0109-UTL
Reply to Office action of July 8, 2003

26 42. (Original) The method of claim 6 wherein said delta-tocopherol enriched tocopherol composition comprises at least 50% delta-tocopherol.

27 43. (Original) The method of claim 6 wherein said delta-tocopherol enriched tocopherol composition comprises at least 65% delta-tocopherol.

28 44. (Original) The method of claim 6 wherein said delta-tocopherol enriched tocopherol composition comprises at least 75% delta-tocopherol.

29 45. (Original) The method of claim 6 wherein said delta-tocopherol enriched tocopherol composition comprises at least 90% delta-tocopherol.

30 46. (Original) The method of claim 6 wherein said delta-tocopherol enriched tocopherol composition comprises at least 95% delta-tocopherol.

31 47. (Original) The method of claim 6 wherein said delta-tocopherol enriched tocopherol composition comprises at least 98% delta-tocopherol.

48. (Canceled)

49. (Canceled)

50. (Canceled)

32 51. (Original) The method of claim 1 wherein said composition is a nutritional composition.

33 52. (Original) The method of claim 1 wherein said composition is a pharmaceutical composition.

34 53. (Original) The method of claim 1 wherein said composition is administered orally.

35 54. (Original) The method of claim 1 wherein said composition is administered parenterally.

36 55. (Original) The method of claim 1 wherein said composition comprises a non-alpha tocopherol in a range of 1-1000 mg per kg body weight of said mammalian subject.

Serial No. 10/020,450
Docket No. 0109-UTL
Reply to Office action of July 8, 2003

37 56. (Original) The method of claim 1 wherein said composition comprises a non-alpha tocopherol in a range of 1-50 mg per kg body weight of said mammalian subject.

38 57. (Original) The method of claim 1 wherein said composition comprises a non-alpha tocopherol in a range of 10-100 mg per kg body weight of said mammalian subject.

39 58. (Previously presented) The method of claim 1, wherein said neuronal damage is neuronal cell death.

40 59. (Previously presented) The method of claim 1, wherein said neuronal damage is total cerebral infarct volume.

41 60. (Previously presented) The method of claim 1, wherein said neuronal damage is total cerebral ischemic damage.

42 61. (Previously presented) The method of claim 1, wherein said neuronal damage is cerebral tissue edema.

43 62. (Previously presented) The method of claim 1, wherein said neuronal damage is cognitive dysfunction.